A Phase 1/2 interventional study of Droxidopa and Placebo in Menkes Disease and Occipital Horn Syndrome, sponsored by Stephen G. Kaler, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Stephen G. Kaler, MD · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Autonomic Nervous System Diseases with a site in United States — 12 open to participants now, 16 under way, none of them phase 3. Autonomic Nervous System Diseases · United States.
Among the 49 studies in Autonomic Nervous System Diseases with a site in United States, this one is the 29th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2021, is one of 4 in phase 1/2, and was the 31st registered.
108 studies on the registry are indexed under Autonomic Nervous System Diseases; 29 are open to participants now.
Browse Autonomic Nervous System Diseases studies →12 of the 49 studies in Autonomic Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:
Stephen G. Kaler · Sites in United States
Ages 7–17
VA Office of Research and Development · Sites in United States
Ages 22–88 · Healthy volunteers
Medical College of Wisconsin · Sites in United States
Ages 11–18 · Women only · Healthy volunteers
National Institute of Neurological Disorders and Stroke (NINDS) · Sites in United States
Ages 18–110
University of California, Los Angeles · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Autonomic Nervous System Diseases studies recruiting now, 6 (29%) set no upper age limit and 12 (57%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 9 · Phase 3 2 · Phase 4 1
First in 1994; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 40 across 72 interventional studies indexed under Autonomic Nervous System Diseases.
Median enrollment 20 across the 31 interventional studies, 63 across the 18 observational. Of the 30 that completed or were terminated, 6 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 49 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Stephen G. Kaler, MD as lead sponsor.
Stephen G. Kaler, MD has 1 study filed under Autonomic Nervous System Diseases — fewer than ten, so there is no comparison to draw.
5 of the studies in Autonomic Nervous System Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01988883Vanderbilt University Medical CenterModafinil and Cognitive Function in POTS | 2026-12 |
| NCT05400174University of California, San DiegoBlood Pressure Effects on Cognition and Brain Blood Flow in PD | 2026-12-15 |
| NCT02725060Vanderbilt University Medical CenterAutoimmune Basis for Postural Tachycardia Syndrome | 2027-02 |
| NCT04100486Northwell HealthNon-Invasive Bioelectronic Analytics | 2027-07 |
| NCT06419959VA Office of Research and DevelopmentNightWare and Cardiovascular Health in Veterans With PTSD | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 49 studies in Autonomic Nervous System Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe complications of their illness or adults with occipital horn syndrome (OHS), who have trouble with intermittent low blood pressure and other symptoms of dysautonomia. The outcomes and information from this study may help adult survivors of Menkes disease and individuals with OHS lead more normal day-to-day lives.
This pilot clinical trial will evaluate the safety, tolerability, dosing, and preliminary efficacy of Northera (Droxidopa) treatment in young adults who survived the major neurodegenerative and neurocognitive effects of Menkes disease through early Copper Histidinate treatment. We hypothesize that Northera (Droxidopa) in Menkes disease survivors with symptoms of dysautonomia (e.g., syncope, dizziness, orthostatic hypotension, abnormal sinoatrial conduction, nocturnal bradycardia, and bowel or bladder dysfunction) from persistent deficiency of the copper-dependent enzyme, dopamine-β-hydroxylase, will be safe, and correct or improve blood neurochemical levels, raise systolic blood pressure, and produce symptomatic improvement and better overall quality of life. We will test this hypothesis in six to ten Menkes disease survivors or OHS patients in a double-blind placebo-controlled randomized crossover clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Northera (Droxidopa) (Treatment A) will be provided to adult subjects as a capsule with 100mg, 200mg, or 300mg of Northera (Droxidopa) contained within gelatin color capsules (sky blue and white, size 0) based on findings from the dose titration visit. These capsules are physically indistinguishable from the Treatment B (placebo) capsules. Frequency of administration (by mouth) will be twice daily for six weeks.
Drug: Droxidopa
Empty gelatin color capsules (sky blue and white, size 0) filled with cellulose microcrystalline and physically indistinguishable from Treatment A capsules. Frequency of administration (by mouth) will be twice daily for six weeks
Other: Placebo
Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.
Also known as: Northera
Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.
Treatment Related Adverse Events as Assessed by CTCAE v4.0
Treatment related adverse events as assessed by CTCAE v 4.0 by study arm
Time frame: TEAEs in 6 week periods of either active drug (droxidopa) or placebo
Mean Change in Systolic Blood Pressure in Tilt Position
Change in systolic BP in tilt position during each treatment arm (droxidopa and placebo) compared to baseline.
Time frame: Change in systolic BP in tilt position during each 6 week treatment arm (droxidopa and placebo) compared to baseline.
Mean Change in Diastolic Blood Pressure in Tilt Position
The change in diastolic BP in tilt position during each treatment arm (droxidopa and placebo) compared to baseline.
Time frame: The change in diastolic BP in tilt position during each 6 week treatment arm (droxidopa and placebo) compared to baseline.
Plasma Catechol Levels
Change in plasma catechols between placebo and droxidopa treatment arms
Time frame: Change in plasma catechols between each 6 week treatment arm (droxidopa and placebo)
Change From Baseline in Daily Bowel Movements
Change from baseline in daily bowel movements
Time frame: Change from baseline in daily bowel movements per day during each 6 week treatment arm (droxidopa and placebo).
Change From Baseline in Time Standing Duration
Change from baseline in Time standing duration
Time frame: Change from baseline in standing time duration during each 6 week treatment arm (droxidopa and placebo).
Change From Baseline in Timed Up and Go (TUG) Test Performance
Change from baseline in Timed Up and Go (TUG) test performance
Time frame: Change from baseline in TUG test performance during each 6 week treatment arm (droxidopa and placebo)
Change From Baseline in 6 Minute Walk Test Performance
Change from baseline in 6 minute walk test performance
Time frame: Change from baseline in the 6MW distance during each 6 week treatment arm (droxidopa and placebo)
Change From Baseline in Scores on the Orthostatic Hypotension Symptom Assessment (OHSA) Questionnaire
Change from baseline in scores on the Orthostatic Hypotension Symptom Assessment questionnaire. The scale rates the severity of OH symptoms from 0 to 10 ; with 10 defined as the worst possible.
Time frame: Change from baseline in OHSA score during each 6 week treatment arm (droxidopa and placebo)
Three adult participants were consented and screened for eligibility between July 2021 and October 2023.
| Milestone | Arm 1 (Northera™ (Droxidopa) First Then Placebo) | Arm 2- Placebo First Then Northera (Droxidopa) |
|---|---|---|
| Started | 1 | 2 |
| Completed | 1 | 2 |
| Not completed | 0 | 0 |
| Milestone | Arm 1 (Northera™ (Droxidopa) First Then Placebo) | Arm 2- Placebo First Then Northera (Droxidopa) |
|---|---|---|
| Started | 01 | 02 |
| Completed | 01 | 02 |
| Not completed | 0 | 0 |
| Milestone | Arm 1 (Northera™ (Droxidopa) First Then Placebo) | Arm 2- Placebo First Then Northera (Droxidopa) |
|---|---|---|
| Started | 01 | 02 |
| Completed | 01 | 02 |
| Not completed | 0 | 0 |
Change in systolic BP in tilt position during each treatment arm (droxidopa and placebo) compared to baseline.
| mm/Hg | Northera (Droxidopa) | Placebo |
|---|---|---|
| Mean Change in Systolic Blood Pressure in Tilt Position | -25 ± 12.5 | -22 ± 6.5 |
The change in diastolic BP in tilt position during each treatment arm (droxidopa and placebo) compared to baseline.
| mmHg | Northera (Droxidopa) | Placebo |
|---|---|---|
| Mean Change in Diastolic Blood Pressure in Tilt Position | -8.6 ± 7.5 | -15 ± 4.5 |
Change in plasma catechols between placebo and droxidopa treatment arms
| pg/ml | Northera (Droxidopa) | Placebo |
|---|---|---|
| Plasma Catechol Levels | 65 ± 8 | 20 ± 4 |
Change from baseline in daily bowel movements
| bowel movements per day | Northera™ (Droxidopa) | Placebo |
|---|---|---|
| Change From Baseline in Daily Bowel Movements | 7 ± 7 | 8 ± 8 |
Change from baseline in Time standing duration
| Seconds | Northera (Droxidopa) | Placebo |
|---|---|---|
| Change From Baseline in Time Standing Duration | 300 ± 50 | 175 ± 25 |
Change from baseline in Timed Up and Go (TUG) test performance
| seconds | Northera (Droxidopa) | Placebo |
|---|---|---|
| Change From Baseline in Timed Up and Go (TUG) Test Performance | 10 ± 2 | 9 ± 1 |
Change from baseline in 6 minute walk test performance
| meters | Northera (Droxidopa) | Placebo |
|---|---|---|
| Change From Baseline in 6 Minute Walk Test Performance | 250 ± 75 | 200 ± 75 |
Treatment related adverse events as assessed by CTCAE v 4.0 by study arm
| adverse events | Northera (Droxidopa) | Placebo |
|---|---|---|
| Treatment Related Adverse Events as Assessed by CTCAE v4.0 | 10 | 6 |
Change from baseline in scores on the Orthostatic Hypotension Symptom Assessment questionnaire. The scale rates the severity of OH symptoms from 0 to 10 ; with 10 defined as the worst possible.
| Scores on a scale | Northera (Droxidopa) | Placebo |
|---|---|---|
| Change From Baseline in Scores on the Orthostatic Hypotension Symptom Assessment (OHSA) Questionnaire | -0.67 (-1.55 to 0.22) | 0 (0 to 0) |
Collected over From enrollment up to 20 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label: Northera (Droxidopa) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Crossover: Northera (Droxidopa) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Crossover: Placebo | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Event | Open Label: Northera (Droxidopa) | Crossover: Northera (Droxidopa) | Crossover: Placebo |
|---|---|---|---|
| VomitingGastrointestinal disorders | 1/3 | 2/3 | 1/3 |
| HeadacheNervous system disorders | 0/3 | 2/3 | 1/3 |
| Elevated blood pressureCardiac disorders | 1/3 | 2/3 | 0/3 |
| potential Urinary Tract infectionRenal and urinary disorders | 0/3 | 1/3 | 0/3 |
| Pre-syncopal episode while on baseline tilt table testNervous system disorders | 0/3 | 0/3 | 1/3 |
| Minimally elevated creatinine levelRenal and urinary disorders | 0/3 | 0/3 | 1/3 |
| Moderate Occult blood noted on urinalysisRenal and urinary disorders | 0/3 | 0/3 | 1/3 |
| SeizureNervous system disorders | 0/3 | 0/3 | 1/3 |
| ProteinuriaRenal and urinary disorders | 0/3 | 0/3 | 1/3 |
| Age, Categorical(Participants) | Northera (Droxidopa) First Then Placebo | Placebo First Then Northera (Droxidopa) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 3 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Northera (Droxidopa) First Then Placebo | Placebo First Then Northera (Droxidopa) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Northera (Droxidopa) First Then Placebo | Placebo First Then Northera (Droxidopa) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 1 | 1 | 2 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Northera (Droxidopa) First Then Placebo | Placebo First Then Northera (Droxidopa) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Northera (Droxidopa) First Then Placebo | Placebo First Then Northera (Droxidopa) | Total |
|---|---|---|---|
| United States | 1 | 2 | 3 |
| Height(cm) | Northera (Droxidopa) First Then Placebo | Placebo First Then Northera (Droxidopa) | Total |
|---|---|---|---|
| Mean | 166.2 (166.2 to 166.2) | 174.85 (173 to 176.7) | 171.97 (166.2 to 176.7) |
| Weight(kg) | Northera (Droxidopa) First Then Placebo | Placebo First Then Northera (Droxidopa) | Total |
|---|---|---|---|
| Mean | 68.0 (68.0 to 68.0) | 52.6 (46.2 to 59) | 57.73 (46.2 to 68) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in Oct 2023, 27 months.
Results were first posted in Apr 2026, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Droxidopa
Autonomic Nervous System Diseases →